Quanterix Investor Presentation — May 2022

Document content

Q1 2022 Earnings Call

MAY 10th, 20222Forward- Looking Statements & Non- GAAP Financial Measures

This presentation contains forward -looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other w ords or

expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward -

looking statements in this presentation are based on Quanterix ’ expectations and assumptions as of the date of this presentation.

Each of these forward -looking statements involves risks and uncertainties. Factors that may cause Quanterix ’ actual results to differ

from those expressed or implied in the forward-looking statements in this presentation are discussed in Quanterix ’ filings with the U.S.

Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix

assumes no obligation to update any forward -looking statements contained herein to reflect any change in expectations, even as n ew

information becomes available.INSTRUMENTS CONSUMABLES ACCELERATOR RADxOTHER

GM % 60.1% 49.3%Q1 2022 Results – 3 yrCAGR

Instruments Consumables RADx Accelerator Other Services-10.6%+27.9%

-100.0%+12.0%Q1 2021 Q1 2022Q1 2022

Mix21% 49% 21% n/a 9%

3-yr CAGR 22% 33% 61% n/a 27%

•$29.6M 3- yr CAGR +34%

•FY RUO revenue $122M to $134M, +22% YoY at

midpoint Q1 2022 Earnings Call Q1 2022 Revenue StratificationEXECUTIVE SESSION 1

Academia +3%Neurology +77%

Asia +154% Instruments -11%Consumables +28%

** Incl. Immunology &

GROWTHCUSTOMER DISEASESPRODUCTS